Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
Titel:
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
Auteur:
Eggermont, Alexander MM. Meshcheryakov, Andrey Atkinson, Victoria Blank, Christian U. Mandala, Mario Long, Georgina V. Barrow, Catherine Di Giacomo, Anna Maria Fisher, Rosalie Sandhu, Shahneen Kudchadkar, Ragini Ortiz Romero, Pablo Luis Svane, Inge Marie Larkin, James Puig, Susana Hersey, Peter Quaglino, Pietro Queirolo, Paola Stroyakovskiy, Daniil Bastholt, Lars Mohr, Peter Hernberg, Micaela Chiarion-Sileni, Vanna Strother, Matthew Hauschild, Axel Yamazaki, Naoya van Akkooi, Alexander CJ. Lorigan, Paul Krepler, Clemens Ibrahim, Nageatte Marreaud, Sandrine Kicinski, Michal Suciu, Stefan Robert, Caroline